Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) FCF Margin (2016 - 2025)

Historic FCF Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to 24.62%.

  • Amphastar Pharmaceuticals' FCF Margin rose 4800.0% to 24.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.66%, marking a year-over-year decrease of 78600.0%. This contributed to the annual value of 23.55% for FY2024, which is 9900.0% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its FCF Margin stood at 24.62% for Q3 2025, which was up 4800.0% from 14.35% recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year FCF Margin high stood at 36.6% for Q1 2022, and its period low was 4.14% during Q3 2021.
  • Moreover, its 5-year median value for FCF Margin was 22.07% (2023), whereas its average is 18.81%.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' FCF Margin plummeted by -280700bps in 2022, and later skyrocketed by 335700bps in 2023.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' FCF Margin stood at 27.76% in 2021, then crashed by -76bps to 6.6% in 2022, then rose by 23bps to 8.1% in 2023, then increased by 10bps to 8.91% in 2024, then surged by 176bps to 24.62% in 2025.
  • Its FCF Margin was 24.62% in Q3 2025, compared to 14.35% in Q2 2025 and 14.3% in Q1 2025.